Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Licenses RT-PCR IP From Roche, Ortho Clinical Diagnostics

NEW YORK (GenomeWeb News) — Qiagen on Monday said it has licensed real-time PCR technology from Roche and from Ortho Clinical Diagnostics.
 
Under the agreement with Roche, Qiagen said it expands an existing arrangement to include all of Roche’s RT-PCR patents and pending patents. Qiagen said the agreement includes rights to patents for enzymes, improved PCR, and pathogen-specific patents.
 
Through the Ortho agreement, Qiagen has licensed rights to patents for a taq-polymerase antibody method that speeds up the activation of PCR enzymes in the early phases of the process.
 
Qiagen said that these licenses expand its portfolio of assays and diagnostics using “almost any” basic IVD-related PCR and real-time PCR.
 
Financial terms of the agreements were not released.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.